MRVI Overview

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Its segments include TriLink and Cygnus. Its TriLink segment provides nucleic acid products and related services, including messenger ribonucleic acid (mRNA), oligonucleotides, CleanCap mRNA capping technology, ModTail poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, enzymes, and mRNA manufacturing services. Its Cygnus segment provides biologics safety testing products and services, including host cell protein enzyme-linked immunosorbent assay (ELISA) kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services. Its TriLink and Cygnus segments produce materials used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products.

Wall Street analysts forecast MRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRVI is4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Maravai LifeSciences Holdings Inc revenue for the last quarter amounts to 65.84M USD, increased 40.53

Maravai LifeSciences Holdings Inc. EPS for the last quarter amounts to -0.03 USD, decreased -85.71

Maravai LifeSciences Holdings Inc (MRVI) has 435 emplpoyees as of May 12 2026.

Today MRVI has the market capitalization of 1.22B USD.